NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/26/2026 13:23
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization585.43 mln
Float56.91 mln
Earnings Date08/19/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
19.62
Transformational upside
Relative Strength
12
/ 100
Significantly lagging
Debt / Equity
0.36
Low leverage
ROE
-62.56
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Candel Therapeutics is a clinical-stage company working to develop new treatments that use the immune system to fight cancer. Its pipeline includes two drug candidates currently in clinical trials ? one targeting prostate cancer and lung cancer, and another focused on a difficult-to-treat form of brain cancer. The company also operates a proprietary discovery platform based on modified herpes simplex virus technology, designed to generate new immunotherapy options for patients with solid tumors. Founded in 2003 and based in Needham, Massachusetts, Candel was previously known as Advantagene Inc.
